Home > > > > Report Detail

Global Biopharmaceutical CMO Market - Analysis By Region, By Country: Opportunities and Forecast (2018-2023) -- By Region (North America, Europe, APAC), By Country (U.S, Denmark, Germany, Switzerland, Korea, Japan, China)

Publisher Name :
Date: 18-Jul-2018
No. of pages: 100

Executive Summary

A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of the global biopharmaceutical Contract Manufacturing Organisation (CMO) market. The report titled “Global Biopharmaceutical CMO Market - Analysis By Region, By Country: Opportunities and Forecast (2018-2023)” analyses the global market as well as the market by Region (North America, Europe and Asia Pacific) and by Country (U.S, Denmark, Germany, Switzerland, Korea, Japan, China).

According to Azoth Analytics research report “Global Biopharmaceutical CMO Market - Analysis By Region, By Country: Opportunities and Forecast (2018-2023)”, the global market value is projected to display a steady growth represented by a CAGR of 14.36% during the forecast period of 2018 – 2023.

Amongst the regions, Europe accounts for the largest share by value in global Bio CMO market in 2017. Additionally, Asia Pacific will be a growing region in the forecasted period, 2018-2023 as population is increasing along with growing number of pharmaceutical requirements. Growing number of chronic diseases is also supporting the market of Bio CMO industry.

The report titled “Global Biopharmaceutical CMO Market - Analysis By Region, By Country: Opportunities and Forecast (2018-2023)” has covered and analyzed the potential of Global Bio CMO Market and provides statistics and information on market size, shares and growth factors. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the global Bio CMO market. Additionally, the report also assesses the financial performance and strategies of various companies operating in the Biopharmaceutical CMO market.

Scope of the Report

Global Bio CMO Market (Actual Period: 2013-2017, Forecast Period: 2018-2023


  • Global Bio CMO Market – By value

  • • By Type – Mammalian & Microbial


Regional Markets – North America, Europe, APAC (Actual Period: 2013-2017, Forecast Period: 2018-2023)


  • Bio CMO Market – By value


Country Analysis - U.S, Denmark, Germany, Switzerland, Korea, Japan, China and Others


  • Bio CMO Market – By value


Other Report Highlights


  • Market Dynamics – Drivers and Restraints

  • Company Analysis – Lonza, Boehringer Ingelheium, Samsung Biologics, Wuxi Biologics

Global Biopharmaceutical CMO Market - Analysis By Region, By Country: Opportunities and Forecast (2018-2023) -- By Region (North America, Europe, APAC), By Country (U.S, Denmark, Germany, Switzerland, Korea, Japan, China)

Table of Contents

1. Research Methodology

2. Executive Summary

3. Biopharmaceutical CMO Market Outlook

4. Global Bio CMO Market : Growth and Forecast
4.1 Global Bio CMO Market, By Value (2013-2017) (USD Billion)
4.2 Global Bio CMO Market, By Value (2018-2023) (USD Billion)

5. Global Biopharmaceutical Market: Segment Analysis

6. North America Bio CMO Market: Growth and Forecast
6.1 North America Market, By Value (2013-2017)(USD Billion)
6.2 North America Market, By Value (2018-2023)(USD Billion)

7. U.S Bio CMO Market, By indications

8.  Canada Bio CMO Market , By Indications

9. Europe Bio CMO Market: Growth and Forecast
9.1 Europe Market, By Value (2013-2017)(USD Billion)
9.2 Europe Market, By Value (2018-2023)(USD Billion)

10. Germany Bio CMO Market, By indications

11. U.K Bio CMO Market, By indications

12. France Bio CMO Market, By indications

13. APAC Bio CMO Market : Growth and Forecast
13.1 APAC Market, By Value (2013-2017)(USD Billion)
13.2 APAC Market, By Value (2018-2023)(USD Billion)

14. China Bio CMO Market, By indications

15. India Bio CMO Market, By indications

16. Japan Bio CMO Market, By indications

17. Bio CMO Market: Country Analysis
17.1 U.S Bio CMO Market, By Value (2013-2023) (USD Billion)
17.2 Denmark Bio CMO Market, By Value (2013-2023) (USD Billion)
17.3 Germany Bio CMO Market, By Value (2013-2023) (USD Billion)
17.4 Switzerland Bio CMO Market, By Value (2013-2023) (USD Billion)
17.5 Korea Bio CMO Market, By Value (2013-2023) (USD Billion)
17.6 Japan Bio CMO Market, By Value (2013-2023) (USD Billion)
17.7 China Bio CMO Market, By Value (2013-2023) (USD Billion)
17.8 Others Bio CMO Market, By Value (2013-2023) (USD Billion)

18. Global Bio CMO  Market Dynamics
18.1 Global Bio CMO Market Drivers
18.2 Global Bio CMO Market Challenges

19. Company Profiles
19.1 Lonza
19.2 Boehringer Ingelheium
19.3 Samsung Biologics
19.4 Wuxi Biologics

List of Tables
Table 1: Japan Biopharmaceutical Market  (100 million USD)

List of Figures
Figure 1: Global In House Manufacturing  By Value, 2013-2017 (USD Billion)
Figure 2: Global In House Manufacturing  By Value, 2013-2017 (USD Billion)
Figure 3: Global Bio CMO Market Size, By Value, 2013-2017 (USD Billion)
Figure 4: Global Biologics market Outlook, 2012-2016 (In Billion )
Figure 5: Global Biologics market Outlook, 2012-2016 (In Billion)
Figure 6: Global Healthcare Expenditure, 2012-2016 (In Trillion)
Figure 7: Number of people with diabetes worldwide and per region in 2017 and 2045, (20-79 years)
Figure 8: Diabetes Prevalence, By Country, in % of population ages 20 to 79 in 2017  
Figure 9: Global Bio CMO Market Size, By Value, 2018-2023 (USD Billion)
Figure 10: Global Bio CMO Market  Size, By Segment, 2017 (%)
Figure 11: Global Bio CMO Market  Size, By Segment, 2023 (%)
Figure 12: North America Bio CMO Size, By Value, 2013-2017 (USD Billion)
Figure 13: North America Bio CMO Market Size, By Value, 2018-2023(USD Billion)
Figure 14: North America GDP, 2013-2017 (USD Trillion)
Figure 15: North America GDP, By Select Country, 2016 (USD Trillion)
Figure 16: North America Healthcare Cost Per Capita, By Select Country, 2016 (USD)
Figure 17: Number of Citizen 65 years and above, USA and Canada in Million  2016
Figure 18: Number of Citizen 65 years and above, USA and Canada in Million  2060
Figure 19: North America Prevalence of Gynecological Disorders (2012-2016)  
Figure 20: Total Number of People with North America Neglected Tropical  Disorders (2012-2016)  
Figure 21: Total Number of  People in North America with Different Type of Cardiovascular Disease  in 2016
Figure 22: North America DALYs of Ischemic Heart Disease(2013-2016 %)
Figure 23: North America DALYs of  Chronic Kidney Disease(2013-2016 %)
Figure 24: North America  DALYs of  Chronic Obstructive Pulmonary Disease(2013-2016 %)
Figure 25: North America DALYs of Alzheimer Disease and Other  Dementias (2013-2016 %)
Figure 26: North America DALYs of Diabetes Mellitus(2013-2016 %)
Figure 27: United States Prevalence of Diabetes  (Per 1,00,000 )2013-2016
Figure 28: United States Prevalence of Musculoskeletal Disorders (Per 1,00,000 )2013-2016
Figure 29: Prevalence of Neurological Disorders in United States (2016, Million)
Figure 30: United States Prevalence  of Cardiovascular Disorders  (Per 1,00,000 )2013-2016
Figure 31: United States DALYs of Ischemic Heart Disease (2013-2016 %)
Figure 32: United States DALYs of  Chronic Kidney Disease(2013-2016 %)
Figure 33: United States DALYs of  Chronic Obstructive Pulmonary Disease(2013-2016 %)
Figure 34: United States DALYs of Alzheimer Disease and Other  Dementias (2013-2016 %)
Figure 35: United States DALYs of Diabetes Mellitus (2013-2016 %)
Figure 36: Canada Prevalence of Diabetes Mellitus (Per 1,00,000 )2013-2016
Figure 37: Canada Prevalence of Musculoskeletal Disorders (Per 1,00,000 )2013-2016
Figure 38: Canada  Total Number of People With Sense Organ Disorders (2012-2016)
Figure 39: Canada Prevalence  of Cardiovascular Disorders  (Per 1,00,000 )2013-2016
Figure 40: Canada DALYs of Ischemic Heart Disease (2013-2016 %)
Figure 41: Canada DALYs of  Chronic Kidney Disease(2013-2016 %)
Figure 42: Canada DALYs of  Chronic Obstructive Pulmonary Disease(2013-2016 %)
Figure 43: Canada DALYs of Alzheimer Disease and Other  Dementias (2013-2016 %)
Figure 44: Canada DALYs of Diabetes Mellitus (2013-2016 %)
Figure 45: Europe Bio CMO Size, By Value, 2013-2017 (USD Billion)
Figure 46: Europe Bio CMO Market Size, By Value, 2018-2023(USD Billion)
Figure 47: Number Deaths due to cancer in Europe 2016
Figure 48: Share of older population 65 years and above as percentage of total population
Figure 49: Western Europe Prevalence of Gynecological (2012-2016, Million)
Figure 50: Western Europe Prevalence of Musculoskeletal  Disorders (2012-2016, Million)  
Figure 51: Total Number of People With Cardiovascular Disorders in Western  Europe, By Type,2016
Figure 52: Western Europe DALYs of Ischemic Heart Disease (2013-2016), in %
Figure 53: Western Europe DALYs of  Chronic Kidney Disease(2013-2016)in %
Figure 54: Western Europe DALYs of  Chronic Obstructive Pulmonary Disease(2013-2016 %)
Figure 55: Western Europe DALYs of Alzheimer Disease and Other  Dementias (2013-2016 )in %
Figure 56: Western Europe DALYs of Diabetes Mellitus (2013-2016 )in %
Figure 57: Germany Prevalence of Musculoskeletal Disorders (Per 1,00,000 )2013-2016
Figure 58: Total Number of People With Infectious Disorder in Germany (2012-2016)
Figure 59: Germany Prevalence of Neurological Disorders (2012-2016, Million)
Figure 60: Germany Prevalence  of Cardiovascular Disorders  (Per 1,00,000 )2013-2016
Figure 61: Germany DALYs of Ischemic Heart Disease (2013-2016), in %                      
Figure 62: Germany DALYs of  Chronic Kidney Disease (2013-2016), in %
Figure 63: Germany DALYs of  Chronic Obstructive Pulmonary Disease(2013-2016), in%
Figure 64: Germany DALYs of Alzheimer Disease and Other  Dementias (2013-2016), %
Figure 65: Germany  DALYs of Diabetes Mellitus (2013-2016), %
Figure 66: United Kingdom DALYs of Ischemic Heart Disease (2013-2016), %                         
Figure 67: United Kingdom DALYs of  Chronic Kidney Disease(2013-2016), %
Figure 68: United Kingdom DALYs of  Chronic Obstructive Pulmonary Disease(2013-2016 %)
Figure 69: United Kingdom DALYs of Alzheimer Disease and Other Dementias (2013-2016 %)
Figure 70: United Kingdom DALYs of Diabetes Mellitus (2013-2016 %)
Figure 71: United Kingdom Prevalence  of Cardiovascular Disorders (Per 1,00,000), 2013-2016
Figure 72: United Kingdom Prevalence of Diabetes Mellitus  (Per 1,00,000), 2013-2016
Figure 73: United Kingdom Prevalence of Musculoskeletal  Disorders (Per 1,00,000), 2013-2016
Figure 74: France DALYs of Ischemic Heart Disease (2013-2016 %)
Figure 75: France DALYs of  Chronic Kidney Disease(2013-2016 %)
Figure 76: France DALYs of  Chronic Obstructive Pulmonary Disease(2013-2016 %)
Figure 77: France DALYs of Alzheimer Disease and Other  Dementias (2013-2016 %)
Figure 78: France DALYs of Diabetes Mellitus (2013-2016 %)
Figure 79: APAC Bio CMO Size, By Value, 2013-2017 (USD Billion)
Figure 80: APAC Bio CMO Market Size, By Value, 2018-2023(USD Billion)
Figure 81: South East Asia, East Asia, Oceania , DALYs of Ischemic Heart Disease (2013-2016 %)                         
Figure 82: South East Asia, East Asia, Oceania DALYs of  Chronic Kidney Disease(2013-2016 %)
Figure 83: South East Asia, East Asia, Oceania DALYs of  Chronic Obstructive Pulmonary Disease(2013-2016 %)
Figure 84: South East Asia, East Asia, Oceania DALYs of Alzheimer Disease and Other  Dementias (2013-2016 %)
Figure 85: South East Asia, East Asia, Oceania DALYs of Diabetes Mellitus   (2013-2016 %)
Figure 86: China DALYs of Ischemic Heart Disease (2013-2016 %)                         
Figure 87: China DALYs of  Chronic Kidney Disease(2013-2016 %)
Figure 88: China DALYs of  Chronic Obstructive Pulmonary Disease(2013-2016 %)
Figure 89: China  DALYs of Alzheimer Disease and Other  Dementias (2013-2016 %)
Figure 90: China DALYs of Diabetes Mellitus (2013-2016 %)
Figure 91: China Prevalence of Diabetes Mellitus (Per 1,00,000 )2013-2016
Figure 92: China  Prevalence of Musculoskeletal Disorders (Per 1,00,000 )2013-2016
Figure 93: China Prevalence  of Cardiovascular Disorders (Per 1,00,000 )2013-2016
Figure 94: India Prevalence of Diabetes Mellitus (Per 1,00,000)2013-2016
Figure 95: India Prevalence of Musculoskeletal Disorders (Per 1,00,000) 2013-2016
Figure 96: India Prevalence  of Cardiovascular Disorders (Per 1,00,000) 2013-2016
Figure 97: Total Number of People With Infectious Disorder in  India (2012-2016)
Figure 98: India DALYs of Ischemic Heart Disease (2013-2016 %)
Figure 99: India  DALYs of  Chronic Kidney Disease(2013-2016 %)
Figure 100: India DALYs of  Chronic Obstructive Pulmonary Disease(2013-2016 %)
Figure 101: India DALYs of Alzheimer Disease and Other  Dementias (2013-2016 %)
Figure 102: India DALYs of Diabetes Mellitus (2013-2016 %)
Figure 103: Japan DALYs of Ischemic Heart Disease (2013-2016 %)
Figure 104: Japan DALYs of  Chronic Kidney Disease(2013-2016 %)
Figure 105: Japan DALYs of  Chronic Obstructive Pulmonary Disease(2013-2016 %)
Figure 106: Japan DALYs of Alzheimer Disease and Other  Dementias (2013-2016 %)
Figure 107: Japan DALYs of Diabetes Mellitus(2013-2016 %)
Figure 108: Japan Prevalence of Diabetes Mellitus (Per 1,00,000 )2013-2016
Figure 109: Japan Prevalence of Musculoskeletal Disorders (Per 1,00,000 )2013-2016
Figure 110: Japan Prevalence  of Cardiovascular Disorders (Per 1,00,000 )2013-2016
Figure 111: US Bio CMO Size, By Value, 2013-2023 (USD Billion)
Figure 112: US Pharmaceutical Spending 2013-2017 in USD Billion
Figure 113: Revenue of companies engaged in speciality pharmacy in US 2016 (in million USD)
Figure 114: Denmark Bio CMO Size, By Value, 2013-2023 (USD Billion)
Figure 115: Germany Bio CMO Size, By Value, 2013-2023 (USD Billion)
Figure 116: Revenue of Germany Pharmaceutical Industry 2012-2016 in Billion USD
Figure 117: Switzerland Bio CMO Size, By Value, 2013-2023 (USD Billion)
Figure 118: Swiss pharmaceutical industry export 2000
Figure 119: Swiss pharmaceutical industry export 2016
Figure 120: Korea Bio CMO Size, By Value, 2013-2023 (USD Billion)
Figure 121: Japan Bio CMO Size, By Value, 2013-2023 (USD Billion)
Figure 122: China Bio CMO Size, By Value, 2013-2023 (USD Billion)
Figure 123: China Expenditure on Health and Medical Care 2012-2018 (in USD Billion)
Figure 124: Other’s Bio CMO Size, By Value, 2013-2023 (USD Billion)
Figure 125: Lonza, Net Sales, 2014-2017 (In Billion USD)
Figure 126: Boehringer Ingelheim, Net Sales, 2013-2016 (In Million USD)
Figure 127: Boehringer Ingelheim Sales by Region, 2016
Figure 128: Boehringer Ingelheim Sales by Segment, 2016
Figure 129: Samsung Biologics, Net Sales, 2014-2017 (In Million USD)
Figure 130: Samsung Biologics, Biomedicine manufacturing plants, 2017
Figure 131: Wuxi Biologics, Net Sales, 2013-2016 (In Million USD)
Figure 132: Wuxi Biologics, Sales by Region, 2016
Figure 133: Boehringer Ingelheim Sales by Segment, 2016

  • Global Single-Use Technologies For Biopharmaceutical Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 12-Sep-2023        Price: US 3380 Onwards        Pages: 105
    Market Overview of Global Single-Use Technologies For Biopharmaceutical market: According to our latest research, the global Single-Use Technologies For Biopharmaceutical market looks promising in the next 5 years. As of 2022, the global Single-Use Technologies For Biopharmaceutical market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 202......
  • Global Single-Use Technologies For Biopharmaceutical Market Insights: Impact of COVID-19 and Future Expectations to 2028
    Published: 28-Mar-2023        Price: US 3260 Onwards        Pages: 109
    The Single-Use Technologies For Biopharmaceutical market revenue was XX Million USD in 2022, and will reach XX Million USD in 2028, with a CAGR of XX% during 2022-2028. This report elaborates the market size, market characteristics, and market growth of the Single-Use Technologies For Biopharmaceutical industry, and breaks down according to the type, application, and consumption area of Single-Use Technologies For Biopharmaceutical. The report also introduces players in the indust......
  • Global Single-Use Technologies For Biopharmaceutical Market Research Report 2022 - Market Size, Current Insights and Development Trends
    Published: 31-Jan-2023        Price: US 3450 Onwards        Pages: 107
    The report focuses on the Single-Use Technologies For Biopharmaceutical market size, segment size (mainly covering product type, application, and geography), competitor landscape, recent status, and development trends. Furthermore, the report provides strategies for companies to overcome threats posed by COVID-19. Technological innovation and advancement will further optimize the performance of the product, enabling it to acquire a wider range of applications in th......
  • Global Single-Use Technologies For Biopharmaceutical Market Research Report 2021 - Impact of COVID-19 on the Market
    Published: 17-Feb-2022        Price: US 3000 Onwards        Pages: 100
    The Single-Use Technologies For Biopharmaceutical market revenue was xx Million USD in 2016, grew to xx Million USD in 2021, and will reach xx Million USD in 2026, with a CAGR of xx during 2021-2026. Considering the influence of COVID-19 on the global Single-Use Technologies For Biopharmaceutical market, this report analyzed the impact from both global and regional perspectives. From production end to consumption end in regions such as North America, Europe, China, and Jap......
  • Global Single-Use Technologies For Biopharmaceutical Market Development Strategy Pre and Post COVID-19, by Corporate Strategy Analysis, Landscape, Type, Application, and Leading 20 Countries
    Published: 10-Aug-2021        Price: US 4000 Onwards        Pages: 105
    The Single-Use Technologies For Biopharmaceutical market revenue was xx Million USD in 2016, grew to xx Million USD in 2020, and will reach xx Million USD in 2026, with a CAGR of xx during 2020-2026. Global Single-Use Technologies For Biopharmaceutical Market Development Strategy Pre and Post COVID-19, by Corporate Strategy Analysis, Landscape, Type, Application, and Leading 20 Countries covers and analyzes the potential of the global Single-Use Technologies For Biopharmaceutical ......
  • 2020-2025 Global Meales-Mumps-Rubella Vaccines Market Report - Production and Consumption Professional Analysis (Impact of COVID-19)
    Published: 03-Jun-2021        Price: US 3360 Onwards        Pages: 98
    Measles, Mumps and Rubella (MMR) vaccines are a combination of live viruses which are administered in the form of injections. The live viruses are in an inactivated form and are unable to replicate in the human cells while the immune system produces a response and protects against the infection. The vaccine of MMR has a long term effect. This report elaborates the market size, market characteristics, and market growth of the Meales-Mumps-Rubella Vaccines industry, and breaks down accordin......
  • 2020-2025 Global Pegvisomant Market Report - Production and Consumption Professional Analysis (Impact of COVID-19)
    Published: 03-Jun-2021        Price: US 3360 Onwards        Pages: 104
    Pegvisomant(trade name Somavert) is a growth hormone receptor antagonist used in the treatment of acromegaly. This report elaborates the market size, market characteristics, and market growth of the Pegvisomant industry, and breaks down according to the type, application, and consumption area of Pegvisomant. The report also conducted a PESTEL analysis of the industry to study the main influencing factors and entry barriers of the industry. In Chapter 3.4 of the report, the ......
  • 2020-2025 Global Human Mesenchymal Stem Cells (hMSC) Market Report - Production and Consumption Professional Analysis (Impact of COVID-19)
    Published: 03-Jun-2021        Price: US 3360 Onwards        Pages: 126
    This report elaborates the market size, market characteristics, and market growth of the Human Mesenchymal Stem Cells (hMSC) industry, and breaks down according to the type, application, and consumption area of Human Mesenchymal Stem Cells (hMSC). The report also conducted a PESTEL analysis of the industry to study the main influencing factors and entry barriers of the industry. In Chapter 3.4 of the report, the impact of the COVID-19 outbreak on the industry was fully ass......
  • 2020-2025 Global Tricyclic Antidepressant Market Report - Production and Consumption Professional Analysis (Impact of COVID-19)
    Published: 03-Jun-2021        Price: US 3360 Onwards        Pages: 101
    This report elaborates the market size, market characteristics, and market growth of the Tricyclic Antidepressant industry, and breaks down according to the type, application, and consumption area of Tricyclic Antidepressant. The report also conducted a PESTEL analysis of the industry to study the main influencing factors and entry barriers of the industry. In Chapter 3.4 of the report, the impact of the COVID-19 outbreak on the industry was fully assessed. Fully risk asse......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs